Beit Jala Pharmaceutical Manufacturing Co

Beit Jala Pharmaceutical Manufacturing Co maintains a strong liquidity position, with a current ratio of 4.32, indicating that it has more than four times the current assets to cover its current liabilities. The company's liquidity is further supported by cash and equivalents of JOD 1,156,570, which provides a buffer against short-term obligations. The debt-to-equity ratio of 0.06 suggests a conservative capital structure, with minimal reliance on debt financing.

In terms of profitability, the company's return on equity (ROE) of 2.91% and return on assets (ROA) of 2.31% indicate moderate returns relative to its equity and total assets, respectively. These figures are in line with the typical performance of firms in the pharmaceutical industry, where high R&D costs and long development cycles can moderate short-term returns.

The company's revenue is primarily concentrated in its core pharmaceutical manufacturing and distribution operations, with no disclosed geographic diversification in the available data. This suggests a potential concentration risk, as the company's performance is closely tied to the demand for its products in its primary market.

Looking ahead, the company's growth trajectory is expected to remain stable, with no significant changes in revenue or operating performance projected in the next fiscal year. The company's operating income of JOD 423,540 and net income of JOD 427,100 reflect a consistent performance, with no major disruptions in the near term.

The company's risk profile is characterized by low liquidity and dilution risks, with no immediate filing-based flags detected. The low dilution risk is supported by the fact that the number of shares outstanding remains unchanged between basic and diluted shares, indicating no imminent share issuance or dilution. The company's conservative capital structure and strong liquidity position further mitigate financial risk.

Recent events, including filings and transcripts, have not indicated any material changes in the company's operations or strategic direction. The company continues to operate within its core business model, with no significant new product launches or market expansions disclosed in the available data.

Net income surged 55.7% year-over-year to JOD 2.73 million, demonstrating strong recent profitability growth.

The company maintains a low debt-to-equity ratio of 0.06, well below the cohort median of 0.18.

Revenue grew 32.3% year-over-year to JOD 12.78 million, reflecting significant top-line expansion in the latest period.

Long-term debt increased significantly to JOD 3.32 million in FY-4, up from JOD 617,980 in FY0.